Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cachexia, malignancy and tumor necrosis factor alpha (TNF-alpha)].

U Nussinovitch1, Y Shoenfeld

  • 1Center of Autoimmune Diseases, Depatment of Medicine "B", Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Harefuah
|August 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-troponin autoantibodies and the cardiovascular system.

Heart (British Cardiac Society)·2010
Same author

Pathogenic role of anti-endothelial cell antibodies in vasculitis. An idiotypic experimental model.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion.

Arthritis and rheumatism·1996
Same author

Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction.

Israel journal of medical sciences·1996
Same author

Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.

Circulation·1996
Same author

Guillain-Barré as an autoimmune disease.

International archives of allergy and immunology·1996

Cachexia, a wasting syndrome, affects many severe diseases and reduces survival. Anti-tumor necrosis factor alpha (TNFalpha) treatments show promise for managing cachexia in cancer and other conditions.

Area of Science:

  • Biomedical Science
  • Pathophysiology
  • Oncology

Background:

  • Cachexia is a complex metabolic syndrome characterized by involuntary weight loss and muscle wasting, frequently observed in chronic diseases like cancer, COPD, and heart failure.
  • It significantly impacts patient prognosis, diminishing survival rates and reducing the efficacy of treatments such as chemotherapy.
  • The prevalence of cachexia is substantial, affecting up to 80% of patients with advanced metastatic cancer.

Discussion:

  • The precise mechanisms driving cachexia remain incompletely understood, but tumor necrosis factor alpha (TNFalpha) is implicated as a key mediator in its development and progression.
  • Current therapeutic strategies for cachexia are being explored, with a particular focus on interventions targeting inflammatory pathways.
  • This review critically examines existing and emerging anti-cachexia treatments, highlighting the role of anti-TNFalpha therapies.

Related Experiment Videos

Key Insights:

  • Tumor necrosis factor alpha (TNFalpha) is a critical factor in the pathogenesis of cachexia across various disease states.
  • Targeting TNFalpha represents a promising therapeutic avenue for mitigating cachexia and improving patient outcomes.
  • Effective cachexia management is crucial for enhancing survival and treatment effectiveness in patients with chronic and malignant diseases.

Outlook:

  • Further research into the multifaceted pathophysiology of cachexia is essential for developing more targeted and effective treatments.
  • Clinical trials investigating anti-TNFalpha therapies in diverse patient populations are warranted to establish their efficacy and safety.
  • Developing comprehensive strategies that combine anti-inflammatory approaches with nutritional and exercise interventions may offer the best approach to combatting cachexia.